Niagen Bioscience senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at the Nasdaq headquarters in San Francisco, CA.

Niagen Bioscience (NASDAQ: NAGE), founded in 1999 and formerly known as ChromaDex, is the global authority on nicotinamide adenine dinucleotide (NAD+), dedicated to advancing the science of healthy aging. Our scientists collaborate with leading universities and research institutions worldwide to unlock the full potential of NAD+, a vital coenzyme found in every cell that naturally declines with age. Niagen Bioscience is the innovator behind Niagen® (patented nicotinamide riboside, or NR), the world's most extensively researched patented NAD+ booster. Backed by 45+ published human clinical studies, 500+ published scientific studies, and 300+ research collaborations across 30+ countries, Niagen® sets the gold standard for scientific rigor, safety, quality, and transparency. Our portfolio includes Tru Niagen®, the #1 healthy-aging NAD+ supplement in the United States,* and Niagen® Plus, our pharmaceutical-grade nicotinamide riboside platform featuring Niagen™ IV and injectable formulations available through participating healthcare providers with a prescription. Our innovation is protected by an extensive intellectual property portfolio, and our vertically integrated platform spans discovery, clinical research, manufacturing, and commercialization. Headquartered in California with locations in Tustin and Westwood, and home to our Laboratory & Innovation Center in Longmont, Colorado, we continue to shape the future of healthy aging through trusted science. Learn more at [www.niagenbioscience.com](http://www.niagenbioscience.com) or explore careers at jobs.lever.co/niagenbioscience. *Based on the top-selling dietary supplement brands by revenue on the largest U.S. e-commerce marketplace (January 1, 2024–December 31, 2024).